Literature DB >> 27203437

High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins.

Kamila S Gwiazda1, Alexandra E Grier1,2, Jaya Sahni1, Stephen M Burleigh1, Unja Martin1, Julia G Yang1, Nicholas A Popp1, Michelle C Krutein1, Iram F Khan1, Kyle Jacoby1, Michael C Jensen3, David J Rawlings1,2,4, Andrew M Scharenberg1,2,4.   

Abstract

Many future therapeutic applications of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 and related RNA-guided nucleases are likely to require their use to promote gene targeting, thus necessitating development of methods that provide for delivery of three components-Cas9, guide RNAs and recombination templates-to primary cells rendered proficient for homology-directed repair. Here, we demonstrate an electroporation/transduction codelivery method that utilizes mRNA to express both Cas9 and mutant adenoviral E4orf6 and E1b55k helper proteins in association with adeno-associated virus (AAV) vectors expressing guide RNAs and recombination templates. By transiently enhancing target cell permissiveness to AAV transduction and gene editing efficiency, this novel approach promotes efficient gene disruption and/or gene targeting at multiple loci in primary human T-cells, illustrating its broad potential for application in translational gene editing.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27203437      PMCID: PMC5113096          DOI: 10.1038/mt.2016.105

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  34 in total

1.  Distinct requirements of adenovirus E1b55K protein for degradation of cellular substrates.

Authors:  Rachel A Schwartz; Seema S Lakdawala; Heather D Eshleman; Matthew R Russell; Christian T Carson; Matthew D Weitzman
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

Review 2.  Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy.

Authors:  Jennifer L Gori; Patrick D Hsu; Morgan L Maeder; Shen Shen; G Grant Welstead; David Bumcrot
Journal:  Hum Gene Ther       Date:  2015-07       Impact factor: 5.695

3.  Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase.

Authors:  J Boyer; K Rohleder; G Ketner
Journal:  Virology       Date:  1999-10-25       Impact factor: 3.616

Review 4.  High-throughput functional genomics using CRISPR-Cas9.

Authors:  Ophir Shalem; Neville E Sanjana; Feng Zhang
Journal:  Nat Rev Genet       Date:  2015-04-09       Impact factor: 53.242

5.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.

Authors:  Ayal Hendel; Rasmus O Bak; Joseph T Clark; Andrew B Kennedy; Daniel E Ryan; Subhadeep Roy; Israel Steinfeld; Benjamin D Lunstad; Robert J Kaiser; Alec B Wilkens; Rosa Bacchetta; Anya Tsalenko; Douglas Dellinger; Laurakay Bruhn; Matthew H Porteus
Journal:  Nat Biotechnol       Date:  2015-06-29       Impact factor: 54.908

6.  Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells.

Authors:  Van Trung Chu; Timm Weber; Benedikt Wefers; Wolfgang Wurst; Sandrine Sander; Klaus Rajewsky; Ralf Kühn
Journal:  Nat Biotechnol       Date:  2015-03-24       Impact factor: 54.908

7.  Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex.

Authors:  Travis H Stracker; Christian T Carson; Matthew D Weitzman
Journal:  Nature       Date:  2002-07-18       Impact factor: 49.962

8.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

9.  Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.

Authors:  Dawn A Maier; Andrea L Brennan; Shuguang Jiang; Gwendolyn K Binder-Scholl; Gary Lee; Gabriela Plesa; Zhaohui Zheng; Julio Cotte; Carmine Carpenito; Travis Wood; S Kaye Spratt; Dale Ando; Philip Gregory; Michael C Holmes; Elena E Perez; James L Riley; Richard G Carroll; Carl H June; Bruce L Levine
Journal:  Hum Gene Ther       Date:  2013-03-06       Impact factor: 5.695

10.  megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering.

Authors:  Sandrine Boissel; Jordan Jarjour; Alexander Astrakhan; Andrew Adey; Agnès Gouble; Philippe Duchateau; Jay Shendure; Barry L Stoddard; Michael T Certo; David Baker; Andrew M Scharenberg
Journal:  Nucleic Acids Res       Date:  2013-11-26       Impact factor: 16.971

View more
  16 in total

1.  Synthetic biology advances and applications in the biotechnology industry: a perspective.

Authors:  Leonard Katz; Yvonne Y Chen; Ramon Gonzalez; Todd C Peterson; Huimin Zhao; Richard H Baltz
Journal:  J Ind Microbiol Biotechnol       Date:  2018-06-18       Impact factor: 3.346

2.  Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome.

Authors:  Caroline Y Kuo; Joseph D Long; Beatriz Campo-Fernandez; Satiro de Oliveira; Aaron R Cooper; Zulema Romero; Megan D Hoban; Alok V Joglekar; Georgia R Lill; Michael L Kaufman; Sorel Fitz-Gibbon; Xiaoyan Wang; Roger P Hollis; Donald B Kohn
Journal:  Cell Rep       Date:  2018-05-29       Impact factor: 9.423

Review 3.  Advances in Alpha-1 Antitrypsin Gene Therapy.

Authors:  Reka Lorincz; David T Curiel
Journal:  Am J Respir Cell Mol Biol       Date:  2020-11       Impact factor: 6.914

4.  Efficient CRISPR/Cas9 Disruption of Autoimmune-Associated Genes Reveals Key Signaling Programs in Primary Human T Cells.

Authors:  Warren Anderson; Jerill Thorpe; S Alice Long; David J Rawlings
Journal:  J Immunol       Date:  2019-11-13       Impact factor: 5.422

5.  Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles.

Authors:  Zeming Chen; Fuyao Liu; Yanke Chen; Jun Liu; Xiaoying Wang; Ann T Chen; Gang Deng; Hongyi Zhang; Jie Liu; Zhangyong Hong; Jiangbing Zhou
Journal:  Adv Funct Mater       Date:  2017-10-16       Impact factor: 18.808

Review 6.  Cancer diagnosis and immunotherapy in the age of CRISPR.

Authors:  Peter J Cook; Andrea Ventura
Journal:  Genes Chromosomes Cancer       Date:  2018-12-20       Impact factor: 5.006

Review 7.  Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer.

Authors:  Markeshaw Tiruneh G/Medhin; Endeshaw Chekol Abebe; Tekeba Sisay; Nega Berhane; Tesfahun Bekele; Tadesse Asmamaw Dejenie
Journal:  Biologics       Date:  2021-05-31

8.  Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells.

Authors:  Malika Hale; Baeckseung Lee; Yuchi Honaker; Wai-Hang Leung; Alexandra E Grier; Holly M Jacobs; Karen Sommer; Jaya Sahni; Shaun W Jackson; Andrew M Scharenberg; Alexander Astrakhan; David J Rawlings
Journal:  Mol Ther Methods Clin Dev       Date:  2017-01-10       Impact factor: 6.698

9.  Method for Dual Viral Vector Mediated CRISPR-Cas9 Gene Disruption in Primary Human Endothelial Cells.

Authors:  Haixia Gong; Menglin Liu; Jeff Klomp; Bradley J Merrill; Jalees Rehman; Asrar B Malik
Journal:  Sci Rep       Date:  2017-02-15       Impact factor: 4.379

Review 10.  In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease.

Authors:  Cia-Hin Lau; Yousin Suh
Journal:  F1000Res       Date:  2017-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.